Reportstack has announced a new market research publication on MediPoint: Bone Grafts and Substitutes - Global Analysis and Market Forecasts. Although autograft is still perceived as the gold-standard material in bone grafting, the wide array of alternatives available in the market has resulted in a gradual shift towards increased adoption of bone grafts and substitutes (BGS), especially in the US and European markets. In contrast to the general picture in developed countries, autograft bone still represents the most popular option during bone grafting in the Asia-Pacific (APAC) region and South America.
The market for BGS is characterized by rapid technological change, frequent new introductions, changes in customers’ demands and evolving industry standards. An example is the industry’s recent re-evaluation of the expanding utilization of BMPs. Moving forward, the shift to lower-dosed BMPs is expected to be accompanied with continued rise in the sales volume of synthetic bone substitutes in all markets, and increased adoption of cell-based matrices in the US market. Since BGS companies have uncovered new ways of using their technologies to find synergies with spine hardware products, and orthopedic implants to deliver better therapeutic outcomes, future access in the market will hinge on suppliers positioning their products as part of a broader therapy system for bone repair that includes multiple offerings. Meanwhile, companies will need to understand two basic driving forces in the global BGS arena – surgeons who continuously seek improved patient outcomes and healthcare systems who become increasingly concerned about the economics.
Given the negative media literature surrounding Medtronic’s INFUSE Bone Graft, surgeons now hold varied opinions regarding the BMP products. As health executives are scrutinizing purchases and using multiple channels to procure biologics at highly competitive prices, surgeon’s preference is no longer considered the top priority in many hospitals’ decision-making process. How are governments’ cost-containment measures affecting the utilization of different types of BGS products?
Currently, in the BGS market, the lack of reliable studies to demonstrate products’ efficacy in human clinical settings has led to many surgeons reluctant to adopt newly-launched biological products. What are the current adoption levels of different types of BGS products?
Cell-based matrices have received increased enthusiasm in the US market. Yet ongoing scrutiny of the segment may have a negative impact on future growth of this segment. In the years to come, launching and marketing a comprehensive orthobiologics portfolio with a clear value proposition will remain critical to companies’ success.
Market Model Features
An interactive excel forecast model based on primary research interviews with KOLs and industry participants and distributors is included in this report*. This procedure-based model provides bone grafting procedure volumes, BGS product segmentation, product utilization rates, average usage frequencies, average selling prices, and market values over a 10–year period (2011–2020). The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.
*Interactive excel forecast model only available to clients purchasing a site license or higher
What Physicians Think
“What Do Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.
Given the negative media literature surrounding Medtronic’s INFUSE Bone Graft, surgeons now hold varied opinions regarding the BMP products. As health executives are scrutinizing purchases and using multiple channels to procure biologics at highly competitive prices, surgeon’s preference is no longer considered the top priority in many hospitals’ decision-making process. How are governments’ cost-containment measures affecting the utilization of different types of BGS products?
Currently, in the BGS market, the lack of reliable studies to demonstrate products’ efficacy in human clinical settings has led to many surgeons reluctant to adopt newly-launched biological products. What are the current adoption levels of different types of BGS products?
Cell-based matrices have received increased enthusiasm in the US market. Yet ongoing scrutiny of the segment may have a negative impact on future growth of this segment. In the years to come, launching and marketing a comprehensive orthobiologics portfolio with a clear value proposition will remain critical to companies’ success.
Market Model Features
An interactive excel forecast model based on primary research interviews with KOLs and industry participants and distributors is included in this report*. This procedure-based model provides bone grafting procedure volumes, BGS product segmentation, product utilization rates, average usage frequencies, average selling prices, and market values over a 10–year period (2011–2020). The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.
*Interactive excel forecast model only available to clients purchasing a site license or higher
What Physicians Think
“What Do Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.
To view the table of contents and know more details please visit MediPoint: Bone Grafts and Substitutes - Global Analysis and Market Forecasts.
No comments:
Post a Comment